Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ConceptoMed

Explore full profile

Develops and commercialises smart Medtech solutions

Vestvågøy, NorwayFounded 2012Biotech & Life Sciences
Valuation <$5M Last recorded · 2017
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for ConceptoMed and the history behind them.

About ConceptoMed

ConceptoMed AS is a Norwegian medical technology company that develops and commercializes solutions for medical procedures and sample collection. The company was founded in 2012 by M.D. Christian Mide, who currently serves as the CEO. The inspiration for the company's first product came from Dr. Mide's own experience as a physician performing arthrocentesis, where he identified a need for a safer and more efficient way to disconnect syringes from needles.

The company's initial focus was on its Luer-Jack® technology, a medical syringe with a unique lever arm mechanism. This design allows for a one-handed, controlled disconnection of the syringe from a needle or other luer-fit connection, which helps to maintain sterility, reduce the risk of needlestick injuries, and prevent fluid spills. The Luer-Jack® syringe is compatible with standard luer connectors and has received CE Mark approval for sale in Europe and FDA 510(k) clearance in the United States. ConceptoMed has established distribution agreements to market the Luer-Jack® in Europe and the Middle East.

Expanding from its syringe technology, ConceptoMed has developed a portfolio of specimen collection devices under the SampleSUITE™ brand. A key product in this line is the SalivaPOD™, a single-use device designed for the clean and easy collection of saliva samples for diagnostic testing, including PCR analysis. Developed to address the challenges of the COVID-19 pandemic and the growing field of saliva-based diagnostics, SalivaPOD™ provides a standardized volume and reduces sample contamination. The company also offers the SalivaCODE™ mobile app, an interactive guide with multilingual instructions for sample collection. The product is CE marked and sold in Scandinavia, with plans to expand distribution globally. Future products in the pipeline include the StoolPOD™ and CapillaryPOD™. ConceptoMed's business model revolves around the development of proprietary medical devices, protected by patents, and sold through international distribution partners to healthcare providers, laboratories, and for at-home use.

Source: Dealroom company data

At a glance

Founded
2012
Headquarters
Vestvågøy, Norway
Sector
Biotech & Life Sciences
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇳🇴 Norway100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ConceptoMed on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ConceptoMed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.